Artiva halts autoimmune cell therapy and cuts 94% of staff
San Diego-based biotech Artiva is winding down after two patient deaths and disappointing durability data in an autoimmune trial.
By Standard Topic. AI-generated from the reporting listed under Coverage. Published . Updated .
This story is no longer being updated. It reflects reporting up to .
What happened
Artiva Biotherapeutics has stopped developing its AlloNK autoimmune cell therapy and laid off 94% of its staff. The decision followed the deaths of two patients and durability data that fell short of expectations. The setbacks add to doubts about applying cancer therapy strategies to autoimmune diseases.
Why it matters
The deaths and halted program are setbacks for drugmakers seeking to use cancer treatment approaches for autoimmune diseases.
Coverage
- After two deaths in autoimmune cell therapy trial, Artiva is shutting down (statnews.com)
- Artiva lays off 94% of staff after deaths and durability sink autoimmune cell therapy (Nick Paul Taylor)
More from Health
- Lancet study urges climate change be declared global health emergency
- NIH launches new vaccine injury center under HHS initiative
- Researchers propose six areas to strengthen ClinicalTrials.gov
- Georgia health officials confirm three new measles cases
- Arizona providers warn Medicaid cuts will crowd emergency rooms
- FDA outlines faster approval route for custom gene therapies